Besides the front-line maintenance therapy, is any positive impact of poly (ADP-ribose) polymerase (PARP) inhibitors on recurrent high-grade ovarian cancer?
| Autor: | Li YT; Department of Obstetrics and Gynecology, Kuo General Hospital, Tainan, Taiwan., Wang PH; Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Female Cancer Foundation, Taipei, Taiwan; Department of Medical Research, China Medical University Hospital, Taichung, Taiwan. Electronic address: phwang@vghtpe.gov.tw. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Taiwanese journal of obstetrics & gynecology [Taiwan J Obstet Gynecol] 2024 Sep; Vol. 63 (5), pp. 599-600. |
| DOI: | 10.1016/j.tjog.2024.07.013 |
| Abstrakt: | Competing Interests: Conflicts of interest Dr. Peng-Hui Wang, editorial board members at Taiwanese Journal of Obstetrics and Gynecology, had no role in the peer review process of or decision to publish this article. The other authors declare that they have no conflicts of interest related to the subject matter or materials discussed in this article. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|